Sees low double digit revenue CAGR ex-Rev/Pom from 2020-2025. Sees $8B-$10B growth from in-line brands from 2020-2025. Sees more than $10B revenue from new product portfolio in 2026. Sees operating margin target more than 37% through 2025. Sees $25B NRA for nine new product portfolio in 2030. Comments taken from investor presentation slides.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY:
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Bristol Myers downgraded to Neutral at BofA as more clarity on execution awaited
- Bristol Myers downgraded to Neutral from Buy at BofA
- Bristol Myers’ repotrectinib application validated by EMA
- Edgewise shares still reflect limited credit for EDG-7500, says Wedbush